Negin Goodarzi

Nov 6, 2024 | digitalcommons.library.tmc.edu | Panke Qu |Kai Xu |Julia Faraone |Negin Goodarzi

Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and XBB-derived variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose-vaccinated and bivalent-vaccinated healthcare workers, XBB.1.5-wave-infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant spikes by measuring viral infectivity and membrane fusogenicity.

Nov 6, 2024 | digitalcommons.library.tmc.edu | Julia Faraone |Panke Qu |Negin Goodarzi |Yi-Min Zheng

AbstractImmune evasion by SARS-CoV-2 paired with immune imprinting from monovalent mRNA vaccines has resulted in attenuated neutralizing antibody responses against Omicron subvariants. In this study, we characterized two new XBB variants rising in circulation - EG.5.1 and XBB.2.3, for their neutralization and syncytia formation. We determined the neutralizing antibody titers in sera of individuals that received a bivalent mRNA vaccine booster, BA.4/5-wave infection, or XBB.1.5-wave infection.

Jan 8, 2024 | cell.com | Panke Qu |Kai Xu |Julia Faraone |Negin Goodarzi

Highlights•BA.2.86 is less immune evasive compared to FLip and other XBB variants•BA.2.86 is antigenically more similar to BA.2 and BA.4/5 than XBB variants•MAb S309 is unable to neutralize BA.2.86 possibly contributed by a D339H mutation•The fusion and infectivity of BA.2.86 is higher than XBB variants in CaLu-3 cellsSummaryEvolution of SARS-CoV-2 requires the reassessment of current vaccine measures.

Sep 12, 2023 | biorxiv.org | Panke Qu |Kai Xu |Julia Faraone |Negin Goodarzi

AbstractEvolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity.

Aug 30, 2023 | biorxiv.org | Julia Faraone |Panke Qu |Yi-Min Zheng |Negin Goodarzi

AbstractImmune evasion by SARS-CoV-2 paired with immune imprinting from monovalent mRNA vaccines has resulted in attenuated neutralizing antibody responses against Omicron subvariants. In this study, we characterized two new XBB variants rising in circulation: EG.5.1 and XBB.2.3, for their ability of neutralization and syncytia formation. We determined the neutralizing antibody in sera of individuals that received a bivalent mRNA vaccine booster, BA.4/5 wave infection, or XBB.1.5 wave infection.